Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Patent
1996-03-08
2000-01-11
Kishore, Gollamudi S.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
514 25, 514 27, 514937, 514944, 514969, A61K 9127
Patent
active
060132779
DESCRIPTION:
BRIEF SUMMARY
This application is a 371 of PCT/IB95/00584 filed Jul. 25, 1995.
This invention refers in general to pharmaceutical or cosmetic compositions aimed at improving local microcirculation of the penis in conditions such as erectile impotence of vascular origin in which the cause of the dysfunction is attributable to a deficiency in blood flow to the cavernous bodies.
The invention more specifically refers to pharmaceutical and/or cosmetic compositions able to increase the volume and speed of blood flow in the capillary network of the skin that covers the penis and of the mucosa of the glans penis.
It is known that during the last few years the pathogenetic question as to the real cause of erectile impotence has continued to place ever increasing emphasis on the vascular origin of the problem rather than on the psychological causes. This is due to the continuous improvement of the instrumental techniques available for diagnosis. In a consistent number of cases of impotence it is, therefore, now possible to identify the organic (and not simply functional) origin of the affliction.
This obviously means that medical treatment of impotence reverts less to psychotherapy, favouring drugs or methods that enable adequate treatment of local vascular deficiencies.
It is also known that the various types of impotence due to vascular problems are presently classified in the two following forms: to the penile cavernous bodies; efferents of the cavernous bodies and the system's collector veins.
Whilst it is possible to treat the latter types of impotence, also referred to as "from venous leakage", with fine vascular surgery to reduce the quantity of blood that flows away from the cavernous bodies, therapeutical measures for the former types are scarce and restricted to provoking a pharmacological erection by intracavernous injection of vasodilators such as papaverine and, more recently, prostaglandins or prostacyclins. Intracavernous injection of these substances causes a temporary erection by blocking the efferent routes of exit for the blood that flows into the cavernous bodies. This approach achieves the desired effect, but does not treat the primary causes of the erectile deficiency. It, therefore, represents a temporary therapeutical measure, to be adopted as required, but which is not followed by a progressive improvement of the underlying pathological erectile condition that is at the basis of the problem. The results are, therefore, partial, of limited duration and, as such, unsatisfactory.
Topical medications, containing papaverine, in the form of ointments or gels for local application on the penis in cases of erectile impotence, have recently been proposed. The results are disappointing, since papaverine administered topically does not, in any of the cases, cross the tunica albuginea of the penis nor penetrate directly into the cavernous bodies. The use of nitrates and nitrites also, as such in the form of ointments, gels, or transdermal plasters, has not led to the expected results.
The problem at the basis of this invention, therefore, is to find and make available a pharmaceutical or cosmetic composition able to increase the speed and volume of blood flow in the small arteries and pre-capillary arterioles, especially the small terminal branches of the helicine arteries which lead into the penile cavernous bodies, as well as into the capillaries of the penis skin and the mucosa of the glans penis.
According to this invention, instead of prostacyclins or vasodilators which paralyze the sphygmic activity and the intrinsic tone of the smooth muscle cells of the small arteries, this problem is solved by topical administration of a composition containing a drug with microvasculo-kinetic activity, and, therefore, is able to strengthen the sphygmic activity of the small arteries and consequently the blood volume that reaches the cavernous bodies and the capillaries of the penis within a unit of time. In this manner, opposition is made to the pathological deficiency of the "pumping function" of the small arteries that is
REFERENCES:
patent: 5256652 (1993-10-01), El-Rashidy
patent: 5482039 (1996-01-01), Place
The Merck Index, Tenth Edition, p. 1397.
International Drug Directory, 16th Edition, p. 1272.
S. Budavari, ed., et al., The Merck Index, 11th Edition, 1989, p. 1539.
Lymphology (United States), Mar. 1993, vol. 26, No. 1 pp. 25-27, Casley-Smith, Jr. et al., `Topical treatment of acute hindlimb lymphedema of the rat using a troxerutin-phosphatidycholine complex in liposomal-like microdispersion,` see the whole document.
Br. J. Clin. Pract. (United Kingdom), 1993, vol. 47, No. 3 pp. 118-119, Riley A.J. `Local pharmacotherapy for impotence` see the whole document.
Drugs (New Zealand), 1992, vol. 44, No. 6, pp. 1013-1032, `Hydroxyethylrutosides; A review of its pharmacology, and therapeutic efficacy in venous insufficiency and related disorders`(see abstracts).
Drugs Exp. Clin. Res. (Switzerland), Jul. 1993 vol. 42, No. 9 pp. 627-31, Otomo S. et al., `Prostaglandin El incorporated in lipid microspheres (lipo PG1), `(see the whole document).
Urology (United States), Jul. 1993 vol. 42, No. 1 pp. 73-75, Wolfsen B. et al, `Intraurethral prostaglandin E-2 cream; a possible alternative treatment for erectile dysfunction. `(see the whole document)
Database WPI Week 8606, Derwent Publications Ltd., Long, GB; AN 86-039687 & JP, A,60 260 524 (Nakanashi M.) 23 Dec. 1985 (see abstract).
J. of Urology, vol. 153, Apr. 1995 p. 474A Canning J R et al., `Prostaglandin El as a topical agent for treatment of erectile dysfunction`(see abstract).
J. Urol (United States), Jun. 1995, vol. 153, No. 6 pp. 1828-30, Dysfunction `Topical prostaglandin-El for the treatment of erectile`(see the whole document).
Inpharma S.A.
Kishore Gollamudi S.
LandOfFree
Compositions for topical treatment of erectile impotence does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for topical treatment of erectile impotence, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for topical treatment of erectile impotence will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1459993